Showing results (611-620 of 2,509) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2026
Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic LeukemiaTamer Othman, Ibrahim Aldoss
Clinical Lymphoma, Myeloma & Leukemia|May 9, 2026
Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment FailureMohammad Ahsen Soomro, Mohamed Ahmed, Al Ola Abdallah, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2026
Access to Bispecific Therapies for Multiple Myeloma: An Overview of Barriers and Emerging SolutionsEmmanuel Ekpenyong, Maryam Mohsin, Samer Al Hadidi, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2026
Real-World Treatment Patterns and Outcomes for Patients With Relapsed/Refractory Multiple Myeloma and Prior Exposure to Lenalidomide and Proteasome Inhibitors in the United StatesLuciano J Costa, Sandhya Nair, Marguerite O'Hara, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2026
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for CureJacqueline F Wang, Gilles Salles, Efrat Luttwak
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2026
SOHO State of the Art Updates and Next Questions | Optimizing Frontline Treatment for Peripheral T-Cell LymphomaNeha Akkad, Neha Mehta-Shah
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2026
Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to ImmunotherapiesDavid Martínez-Campuzano, Clara Sopeña, María José Moreno, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 4, 2026
Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel DrugsEvani Jain, Chiranjeevi Sainatham, Prithvi Raghavan, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 2, 2026
SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Megan Metzger, Charles Hertz, John Mascarenhas
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal AntibodiesGary J Schiller, Brea C Lipe, Nizar J Bahlis, et al.
Pageof 251